SC 13G | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Akero Therapeutics, Inc. | 1,876,811 | 5.4% | EDGAR |
SC 13G | 2021-12-13 | Point72 Asset Management, L.P. | Akero Therapeutics, Inc. | 1,747,849 | 5.0% | EDGAR |
SC 13G | 2021-06-30 | Skorpios Trust | Akero Therapeutics, Inc. | 2,346,298 | 6.7% | EDGAR |
SC 13D/A | 2021-06-29 | ATP Life Science Ventures, L.P. | Akero Therapeutics, Inc. | 37,555 | 0.1% | EDGAR |
SC 13D/A | 2021-05-07 | venBio Global Strategic Fund II L.P. | Akero Therapeutics, Inc. | 2,315,893 | 6.6% | EDGAR |
SC 13G/A | 2021-02-16 | Versant Venture Capital VI, L.P. | Akero Therapeutics, Inc. | 777,727 | 2.2% | EDGAR |
SC 13G/A | 2021-02-16 | Atlas Venture Fund XI, L.P. | Akero Therapeutics, Inc. | 2,206,412 | 6.4% | EDGAR |
SC 13G | 2021-02-16 | Redmile Group, LLC | Akero Therapeutics, Inc. | 2,322,557 | 6.7% | EDGAR |
SC 13G/A | 2021-02-11 | JANUS HENDERSON GROUP PLC | Akero Therapeutics, Inc. | 3,493,419 | 10.1% | EDGAR |
SC 13G | 2021-02-11 | ALKEON CAPITAL MANAGEMENT LLC | Akero Therapeutics, Inc. | 2,287,630 | 6.6% | EDGAR |
SC 13G/A | 2021-02-05 | AMGEN INC | Akero Therapeutics, Inc. | 1,508,375 | - | EDGAR |
SC 13G/A | 2020-09-10 | JANUS HENDERSON GROUP PLC | Akero Therapeutics, Inc. | 3,507,228 | 10.1% | EDGAR |
SC 13D/A | 2020-09-09 | venBio Global Strategic Fund II L.P. | Akero Therapeutics, Inc. | 2,668,717 | 7.7% | EDGAR |
SC 13D/A | 2020-07-14 | Apple Tree Partners IV, L.P. | Akero Therapeutics, Inc. | 5,830,203 | 17.2% | EDGAR |
SC 13D/A | 2020-07-08 | venBio Global Strategic Fund, L.P. | Akero Therapeutics, Inc. | 3,033,552 | 10.6% | EDGAR |
SC 13G/A | 2020-02-14 | Versant Venture Capital VI, L.P. | Akero Therapeutics, Inc. | 3,656,585 | 12.8% | EDGAR |
SC 13G | 2020-02-14 | JANUS HENDERSON GROUP PLC | Akero Therapeutics, Inc. | 2,409,533 | 8.4% | EDGAR |
SC 13G | 2020-02-13 | Atlas Venture Fund XI, L.P. | Akero Therapeutics, Inc. | 2,706,412 | 9.5% | EDGAR |
SC 13G | 2020-02-10 | AMGEN INC | Akero Therapeutics, Inc. | 1,905,698 | - | EDGAR |
SC 13D/A | 2020-01-15 | venBio Global Strategic Fund II L.P. | Akero Therapeutics, Inc. | 3,322,138 | 11.6% | EDGAR |